7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,980.87

+421.63

+0.54%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

XETRA - Delayed Quote EUR

Fresenius SE & Co. KGaA (FRE.DE)

47.80 +0.79 (+1.69%)

At close: October 30 at 5:35:18 PM GMT+1

Loading Chart for FRE.DE

Chart Range Bar

Interval:

In partnership with ChartIQ

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ...

Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ...

Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate

Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate

Fresenius (XTRA:FRE) Stock May Still Be Cheap On Its 66% Run

Fresenius (XTRA:FRE) Stock May Still Be Cheap On Its 66% Run

German health care group Fresenius reaffirms earnings outlook

German health care group Fresenius reaffirms earnings outlook

Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?

Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?

Mobilize your Website

View Site in Mobile | Classic

Share by: